Tecentriq

Monotherapy as adjuvant treatment following complete resection for adult patients w/ stage II to IIIA NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells & whose disease has not progressed following platinum-based adjuvant chemotherapy. In combination w/ Avastin, paclitaxel & carboplatin in patients w/ metastatic NSCLC who had not received prior chemotherapy. Monotherapy in patients w/ metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. In combination w/ nab-paclitaxel & carboplatin for 1st-line treatment of patients w/ metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. Monotherapy for 1st-line treatment of patients w/ metastatic NSCLC whose tumors have PD-L1 expression ≥50% tumor cells or ≥10% tumor-infiltrating immune cells (IC) & who do not have EGFR or ALK genomic tumor aberrations. In combination w/ carboplatin & etoposide for 1st-line treatment of patients w/ extensive-stage small cell lung cancer (ES-SCLC). In combination w/ nab-paclitaxel in patients w/ unresectable locally advanced or metastatic triple -ve breast cancer (TNBC) whose tumors have PD-L1 expression of ≥1% on IC & who have not received prior chemotherapy for metastatic disease. In combination w/ Avastin in patients w/ unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

IV Initial dose must be administered over 60 min. If well tolerated, all subsequent infusions may be administered over 30 min. Monotherapy: Metastatic NSCLC 840 mg every 2 wk or 1,200 mg every 3 wk or 1,680 mg every 4 wk until loss of clinical benefit or unacceptable toxicity. Early-stage NSCLC 840 mg every 2 wk or 1,200 mg every 3 wk or 1,680 mg every 4 wk for 1 yr unless disease recurrence or unacceptable toxicity. Combination therapy: Tecentriq 840 mg every 2 wk or 1,200 mg every 3 wk or 1,680 mg every 4 wk. 1st-line non-squamous NSCLC Induction phase: Administer Avastin, paclitaxel & carboplatin every 3 wk. Maintenance: Administer Avastin every 3 wk. 1st-line non-squamous metastatic NSCLC Administer nab-paclitaxel & carboplatin every 3 wk. Administer nab-paclitaxel & carboplatin on day 1 for each 21-day cycle. Administer nab-paclitaxel on days 8 & 15. 1st-line ESCLC Administer carboplatin & etoposide every 3 wk; on day 1 of each cycle & etoposide on days 2 & 3. 1st-line unresectable locally advanced or metastatic TNBC Administer nab-paclitaxel 100 mg/m² on days 1, 8 & 15 of each 28-day cycle. HCC Administer Avastin 15 mg/kg every 3 wk. SC 1,875 mg every 3 wk.

Hypersensitivity.

Cancer Immunotherapy / Targeted Cancer Therapy

L01FF05 - atezolizumab ; Belongs to the class of PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.

POM